Esther Voigt
About
In The Last Decade
Esther Voigt
19 papers receiving 421 citations
Peers
Comparison fields: 5 of 59
- Infectious Diseases 256
- Hepatology 158
- Epidemiology 145
- Virology 128
- Emergency Medicine 102
Countries citing papers authored by Esther Voigt
This map shows the geographic impact of Esther Voigt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther Voigt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther Voigt more than expected).
Fields of papers citing papers by Esther Voigt
This network shows the impact of papers produced by Esther Voigt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther Voigt. The network helps show where Esther Voigt may publish in the future.
Co-authorship network of co-authors of Esther Voigt
This figure shows the co-authorship network connecting the top 25 collaborators of Esther Voigt. A scholar is included among the top collaborators of Esther Voigt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther Voigt. Esther Voigt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 23 | |
| 2 | 14 | |
| 3 | 10 | |
| 4 | 43 | |
| 5 | 14 | |
| 6 | 10 | |
| 7 | ARDS in an HIV-positive patient associated to respiratory syncytial virus. | 7 |
| 8 | 20 | |
| 9 | 7 | |
| 10 | Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring. | 3 |
| 11 | Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. | 2 |
| 12 | 32 | |
| 13 | 30 | |
| 14 | 7 | |
| 15 | Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. | 87 |
| 16 | 72 | |
| 17 | 16 | |
| 18 | 20 | |
| 19 | Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. | 15 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.